Clinical Outcomes of Repeated Radioactive Iodine Therapy for Graves’ Disease

Kim, Min Joo; Cho, Sun Wook; Kim, Ye An; Choi, Hoon; Park, Young Joo; Park, Do Joon; Cho, Bo Youn

doi:10.3803/enm.2022.1418

Cited by 5 publications

(3 citation statements)

References 29 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thyroid size appeared as a significant predictor of treatment failure, with larger thyroid glands (> 60 g) associated with a higher risk of failure. This outcome aligns with the previous literatures [ 8 – 10 , 21 , 22 ]. We did not find other significant factors previously mentioned such as male sex and free T4 [ 8 , 23 ].…”

Section: Discussionsupporting

confidence: 93%

Prospective study to evaluate radioactive iodine of 20 mCi vs 10–15 mCi in Graves’ disease

Kanokwongnuwat,

Penpong

2024

BMC Endocr Disord

View full text Add to dashboard Cite

Objectives To assess whether increasing radioactive iodine dose can increase treatment efficacy in Graves’ disease. Methods A prospective study was conducted, including 106 patients receiving 20 mCi (740 MBq) radioactive iodine (RAI), compared with a retrospective data, including 113 patients receiving 10–15 mCi (370–555 MBq) RAI. Remission and failure rates were evaluated at 6 months post-RAI. Statistical analysis was performed using logistic regression and Kaplan–Meier curves. Results Patients receiving 20 mCi RAI demonstrated a significantly higher remission rate compared to the 10–15 mCi group (82.1% vs 66.4%, p = 0.009). Median time to remission was shorter in the 20 mCI group (3 vs 4 months, p = 0.002). Hypothyroidism at 6 months was more prevalent in the 20 mCi group (67% vs 53%, p = 0.03). Larger thyroid size (> 60 g) was associated with treatment failure (p = 0.02). Conclusions Higher dosage (20 mCi) RAI showed superior efficacy in achieving remission compared to lower dosages (10–15 mCi) in Graves’ disease treatment.

show abstract

Section: Discussionsupporting

confidence: 93%

Prospective study to evaluate radioactive iodine of 20 mCi vs 10–15 mCi in Graves’ disease

Kanokwongnuwat,

Penpong

2024

BMC Endocr Disord

View full text Add to dashboard Cite

show abstract

“…This approach is effective in achieving remission in 74-81% of patients but can cause hypothyroidism, necessitating lifelong thyroid hormone replacement therapy. 21 Thyroidectomy, the surgical removal of the thyroid gland, is a de nitive treatment option for GD and offers a high cure rate. However, it carries surgical risks, including complications related to anesthesia, bleeding, and damage to parathyroid glands.…”

Section: Discussionmentioning

confidence: 99%

Graves' Disease: In Silico Design of Hybrid Molecule Targeting the Thyroid-stimulating Hormone Receptor

Andrade,

de Oliveira,

Silva

et al. 2024

Preprint

View full text Add to dashboard Cite

Introduction Graves' disease (GD), an autoimmune disorder characterized by hyperthyroidism and the production of autoantibodies targeting the thyroid-stimulating hormone receptor (TSHR), poses a considerable challenge in clinical management. Antithyroid medications block thyroid hormone synthesis and are usually the first-line treatment. In recent years, the advent of computational molecule design has offered a promising avenue for the development of novel therapeutic strategies tailored to specific molecular targets. Despite the substantial progress made in silico molecule design for targeting the TSHR in GD, several critical gaps persist in the current literature. Objective To provide an in silico design of hybrid molecule targeting the TSHR. Method In silico hybridization of rituximab (RTX) and methimazole (MMZ) was performed through a comprehensive workflow: structural bioinformatics analysis, virtual screening and hybrid molecule design, molecular dynamics simulations, machine learning-based analysis, pharmacokinetic modeling and safety assessment, free energy calculations, in silico mutation analysis, data analysis and visualization. Result In silico approach identified a novel hybrid molecule candidate with promising potential for the treatment of GD. The designed molecule exhibited favorable characteristics in terms of binding affinity, selectivity, absorption, distribution, metabolism, excretion and toxicity profiles, and potential safety. Conclusion The designed molecule, derived from MMZ and RTX, exhibited promising characteristics in silico. The hybrid molecule demonstrated favorable binding affinity and selectivity towards the TSHR through virtual screening and molecular dynamics simulations.

show abstract

“…The optimal dosage of RAI for achieving remission is recommended with 10-15 mCi (370-555 MBq) [4] which shows a remission rate of 90% [5][6][7][8]. However, there are some reports regarding a lower remission rate of about 50-80% [9][10][11][12]. Correlation between the remission after RAI therapy and administered radiation dose is seen in some studies [6, [13][14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Prospective study to evaluate radioactive iodine of 20 mCi vs 10-15 mCi in Graves’ disease

Kanokwongnuwat,

Penpong

2024

Preprint

View full text Add to dashboard Cite

Objectives To assess whether increasing radioactive iodine dose can increase treatment efficacy in Graves’ disease. Methods A prospective study was conducted, including 106 patients receiving 20 mCi (740 MBq) radioactive iodine (RAI), compared with a retrospective data, including 113 patients receiving 10-15 mCi (370-555 MBq) RAI. Remission and failure rates were evaluated at 6 months post-RAI. Statistical analysis was performed using logistic regression and Kaplan-Meier curves. Results Patients receiving 20 mCi RAI demonstrated a significantly higher remission rate compared to the 10-15 mCi group (82.1% vs 66.4%, p = 0.009). Median time to remission was shorter in the 20 mCI group (3 vs 4 months, p = 0.002). Hypothyroidism at 6 months was more prevalent in the 20 mCi group (67% vs 53%, p = 0.03). Larger thyroid size (>60 grams) was associated with treatment failure (p =0.02). Conclusions Higher dosage (20 mCi) RAI showed superior efficacy in achieving remission compared to lower dosages (10-15 mCi) in Graves’ disease treatment.

show abstract

Clinical Outcomes of Repeated Radioactive Iodine Therapy for Graves’ Disease

Cited by 5 publications

References 29 publications

Prospective study to evaluate radioactive iodine of 20 mCi vs 10–15 mCi in Graves’ disease

Prospective study to evaluate radioactive iodine of 20 mCi vs 10–15 mCi in Graves’ disease

Graves' Disease: In Silico Design of Hybrid Molecule Targeting the Thyroid-stimulating Hormone Receptor

Prospective study to evaluate radioactive iodine of 20 mCi vs 10-15 mCi in Graves’ disease

Contact Info

Product

Resources

About